GH Research (GHRS) to Release Quarterly Earnings on Friday

GH Research (NASDAQ:GHRS - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Friday, May 2nd. Analysts expect GH Research to post earnings of ($0.61) per share for the quarter.

GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. On average, analysts expect GH Research to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GH Research Price Performance

Shares of GH Research stock opened at $9.50 on Friday. The stock has a fifty day moving average price of $10.63 and a 200-day moving average price of $9.63. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The firm has a market cap of $494.27 million, a PE ratio of -12.03 and a beta of 0.84.

Analyst Ratings Changes

GHRS has been the subject of several recent research reports. Stifel Nicolaus lifted their price target on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Cantor Fitzgerald started coverage on shares of GH Research in a research note on Thursday, February 13th. They set an "overweight" rating and a $14.00 price objective for the company. Guggenheim initiated coverage on shares of GH Research in a research note on Thursday, March 13th. They issued a "buy" rating and a $32.00 target price on the stock. Finally, Royal Bank of Canada started coverage on shares of GH Research in a research report on Friday, March 7th. They set an "outperform" rating and a $31.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, GH Research has an average rating of "Buy" and a consensus target price of $30.86.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.